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Large studies in von Willebrand disease patients, including Spanishand Portuguese registries, led to the identification of >250 differentmutations. It is a challenge to determine the pathogenic effect of
potential splice site mutations on VWFmRNA. This study aimed to elu-
cidate the true effects of 18 mutations on VWFmRNA processing, inves-
tigate the contribution of next-generation sequencing to in vivo mRNA
study in von Willebrand disease, and compare the findings with in silico
prediction. RNA extracted from patient platelets and leukocytes was
amplified by RT-PCR and sequenced using Sanger and next generation
sequencing techniques. Eight mutations affected VWF splicing:
c.1533+1G>A, c.5664+2T>C and c.546G>A (p.=) prompted exon skip-
ping; c.3223-7_3236dup and c.7082-2A>G resulted in activation of cryp-
tic sites; c.3379+1G>A and c.7437G>A) demonstrated both molecular
pathogenic mechanisms simultaneously; and the p.Cys370Tyr missense
mutation generated two aberrant transcripts. Of note, the complete
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effect of three mutations was provided by next generation sequencing alone because of low expression
of the aberrant transcripts. In the remaining 10 mutations, no effect was elucidated in the experiments.
However, the differential findings obtained in platelets and leukocytes provided substantial evidence
that four of these would have an effect on VWF levels. In this first report using next generation sequenc-
ing technology to unravel the effects of VWFmutations on splicing, the technique yielded valuable infor-
mation. Our data bring to light the importance of studying the effect of synonymous and missense muta-
tions on VWF splicing to improve the current knowledge of the molecular mechanisms behind von
Willebrand disease. clinicaltrials.gov identifier:02869074.  
Introduction
Von Willebrand disease (VWD), the most common con-
genital bleeding disorder, is caused by a genetic defect in
the von Willebrand factor gene (VWF).1 VWF mutational
analysis can be valuable for diagnosing and investigating
the molecular etiology of VWD, as was seen in the
Spanish (PCM-EVW-ES project) and Portuguese cohort of
VWD patients.2-4 One interesting challenge in this condi-
tion is to elucidate the pathogenic mechanism of VWF
mutations. In silico analysis is considered a suitable sup-
porting tool to predict the pathogenicity of the variants
identified.5,6 However, functional studies remain essential
to unequivocally determine their deleterious effect.7
Functional studies can be performed by analyzing the
potential effect of splice site mutations (PSSM) in RNA. In
addition to splice site consensus sequence mutations,
deep intronic, missense, and synonymous mutations can
also disturb splicing. Along this line, 25% of synonymous
mutations positioned at exon-intron boundaries result in
altered splicing, which, in itself, can cause disease, modify
the severity of the disease phenotype, or be linked with
disease susceptibility.8 In VWF, heterozygotes for PSSM
may be associated with mild forms of VWD type 1 or be
phenotypically silent, but when two such mutations are
found in different alleles, the phenotype is associated
with VWD type 3.9
Almost all related studies of splicing effects have exam-
ined peripheral blood platelets, as VWF is exclusively
expressed in these cells and endothelial cells.10,11 Platelets
are anucleated, but they contain small amounts of transla-
tionally active megakaryocytic mRNA.12,13 In contrast, the
amount of mRNA obtained from leukocytes is higher and
contains mRNA transcripts for genes that are not normal-
ly expressed in these cells, known as ‘‘ectopic transcripts’’.
Their analysis has been used to investigate mutations in
several inherited disorders,14,15 as they facilitate the study
of mRNA of those genes expressed in hard to reach tis-
sues.16 PSSM can affect mRNA reorganization and intro-
duce premature termination codons (PTCs) into open
reading frames, a common cause of genetic disorders.
Most nonsense transcripts are recognized and degraded
by nonsense-mediated mRNA decay (NMD),17 a degrada-
tion pathway to control synthesis of truncated proteins.18
The efficiency of NMD varies between cell types; hence,
the use of RNA from platelets and leukocytes for in vivo
study of VWF PSSM offers complementary results, partic-
ularly when NMD occurs in the allele carrying the muta-
tion in platelets, as we reported.7 
Since its development, next-generation sequencing
(NGS) has been increasingly used in molecular genetics to
identify mutations causing disease. However, few groups
have explored its potential for analyzing splicing variants
following RT-PCR.19,20 In this new scenario, the procedure
we previously described to analyze the effects of PSSM in
VWF7 has been optimized and adapted to an NGS-based
technique to investigate its value in this field. Our main
objective was to elucidate the true effects of 18 selected
mutations (intronic, synonymous, delins, and missense)
on mRNA processing and their genotype/phenotype cor-
respondence by analysis of leukocytes and platelets from
clinical samples. Finally, the in vivo effects of the muta-
tions were compared with the in silico predictions.  
Methods 
Patients
We studied 15 patients diagnosed with different types of VWD,
5 from Complexo Hospitalario Universitario A Coruña, 8 from
Hospital Universitari Vall d’Hebron (HUVH), and 2 from Centro
Hospitalar e Universitário de Coimbra. Samples from 4 healthy
individuals were used as controls. The study was performed
according to the guidelines of the Declaration of Helsinki and was
approved by the local Research Ethics Committee. All partici-
pants provided written informed consent. 
Splice site prediction software
The predicted impact of potential splice site mutations was
analyzed with NetGene221 and the splicing prediction module of
Alamut Visual v.2.6.1 software (Interactive Biosoftware, Rouen,
France), which integrates data from three methods: Splice Site
Prediction by Neural Network (NNSplice), MaxEntScan, and
Human Splicing Finder (HSF). 
Platelet and leukocyte separation and RNA isolation
Leukocyte and platelet RNA from patients and controls was
isolated from 10 mL of peripheral blood collected in EDTA tubes,
as previously described.7 
VWF mRNA amplification 
After RNA isolation, cDNA was synthesized using the High-
Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufacturer’s
recommendations. The region including the mutation was ampli-
fied by Platinum Taq DNA Polymerase (Thermo Fisher Scientific)
in leukocyte and platelet cDNA (Online Supplementary Methods
and Table S1).  PCR products were separated on 1% agarose gel
and visualized by SYBR Safe DNA Gel Stain (Thermo Fisher
Scientific). 
Sanger sequencing and analysis
PCR products were sequenced as previously described.22
However, multiple-band PCR products were previously agarose-
purified using the MiniElute Gel Extraction kit (Qiagen). The
sequences obtained were assembled and aligned against the con-
sensus wild-type (WT) VWF mRNA sequence (GenBank
NM_000552) using SeqScape v2.7 software (Thermo Fisher
Scientific).
Next-generation sequencing and analysis 
PCR amplicons obtained per patient were equimolarly mixed in
a single tube in a total amount of 250 ng. Subsequently, the
libraries were fragmented and the adapter and barcodes were lig-
ated using the NGSgo protocol (GenDX, Utrecht, Netherlands)
following the manufacturer’s recommendations. Resulting
libraries were combined and sequenced on a MiSeq platform
(Illumina, San Diego, CA).
After sequencing, barcoded sequences were demultiplexed and
analyzed individually. The paired sequence files (fastq format)
were used as input for analysis with the CLC Genomic
Workbench v.11 software (Qiagen, Aarhus, Denmark) (Online
Supplementary Methods and Figure S1-S2). 
Results
An in-depth study was performed in PCM-EVW-ES,3 the
Portuguese cohort,4 and HUVH patients to select previous-
ly undescribed VWF mutations and mutations with an
unknown or controversial pathogenic mechanism.
Eighteen mutations (15 patients) were selected: 8 intronic
(4 in canonical, GT and AG, splice site sequences), 5 syn-
onymous, 2 missense, and 3 delins. The patients’ pheno-
typic and molecular data are summarized in Table 1 and
Online Supplementary Table S2. Total mRNA was obtained
from platelets and leukocytes of all patients, with the
exception of patients UMP08 and UMP14, in whom
platelet RNA isolation failed due to blood lysis. All muta-
tions were analyzed by both Sanger sequencing and NGS,
and results were compared to the predictions generated
by in silico analysis (Online Supplementary Table S3).
Mutations in canonical splice site sequences 
The c.1533+1G>A mutation (intron 13) was identified
in a type 3 VWD carrier (UMP01). The exon 11-15 region
was analyzed with a specific primer pair to avoid amplifi-
cation of a prevalent alternative-splicing product (skipping
of exons 14 and 15) in VWF from leukocytes.7 Whereas
only the expected PCR product was observed in platelets,
leukocyte amplification resulted in 4 PCR bands. Sanger
analysis of leukocytes showed 2 mRNA aberrant tran-
scripts: 1) lacking exon 13; and 2) lacking exon 13 and 14
(Online Supplementary Figure S3). By means of NGS, it was
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Table 1. Laboratory and molecular data of VWD patients
Patients code VWD VWF:Ag VWF:RCo FVIII:C NT change AA change Exon Intron Domain
UMP01 3 carrier 70 70.5 111 c.1533+1G>A - - 13 intronic
UMP02 1H 36 49 101 c.3379+1G>A * - - 25 intronic
c.-2627C>T * - - - upstream
UMP03 1 26 21.2 64.8 c.5664+2T>C * - - 33 intronic
c.7220T>C * p.Leu2407Pro 42 - C2
UMP04 1 50 52 47 c.7081+6G>T - - 41 intronic
UMP05 1 27 32 72 c.7730-56C>T - - 45 intronic
UMP06 2A/2M 12 4 24 c.4120C>T * p.Arg1374Cys 28 A1
c.7730-4C>G * - - 45 intronic
UMP07 1 37 28 60 c.8254-5T>G - - 51 intronic
UMP08 1 42.4 41.7 73.4 c.546G>A† p.Ser182 6 - D1
c.4866C>T† p.Asp1622 28 - A1-A3
UMP09‡ 1 51 49.8 71 c.3291C>T p.Cys1097 25 - D3
UMP10 3 carrier 46.4 45 105 c.1109G>A p.Cys370Tyr 9 - D1
UMP11 1 31 24 57 c.3223-7_3236dup p.Pro1079_Tyr1080ins 25 - D3
LeuGlnValAspProGluPro
UMP12 3 3.7 5 6.7 c.449T>C† p.Leu150Pro 5 - D1
c.7082-2A>G† - - 41 intronic
UMP13 2A 117 6.5 90 c.3426T>C§ p.Cys1142 26 - D3
c.3485_3486delinsTG§ p.Pro1162Leu 26 - D3
c.8318G>C† p.Cys2773Ser 52 - CK
UMP14 1 6 6 4,5 c.6699_6702dup† p.Cys2235ArgfsTer8 38 - D4
c.7437G>A† p.Ser2479 43 - C3
UMP15|| 3 2 <1 5 c.546G>A§ p.Ser182 6 - D1
c.7082-2A>G§ - - 41 intronic
c.8155+3G>C† - - 50 intronic
All mutations were identified in heterozygous state. In bold, mutations selected to study their effect on VWF mRNA. The subtype 1H (historical) refers to patients previously diag-
nosed as type 1 VWD that, at the time of enrollment at the PCM-EVW-ES project, show a slight decrease or even a normal VWF plasma levels. AA:amino acid; NT: nucleotide; VWD:
von Willebrand disease. *The allelic phase (cis/trans) of mutations could not be determined since no informative relatives are available. †Mutations in trans. ‡Patient with an addi-
tional mutation in the F8 gene. §Mutations in cis. ||Patient previously studied at mRNA level by Corrales et al.7
determined that 19% were transcripts without exon 13,
45% transcripts without exons 13 and 14, and an addi-
tional aberrant transcript without exon 14 was detected in
8% transcripts (Online Supplementary Table S4). By both
techniques, no effect was visible in platelets due to NMD. 
The c.3379+1G>A mutation (intron 25) was identified
in a type 1H VWD patient (UMP02). We designed two
new primers to analyze the exon 22-26 region.
Amplification of leukocyte cDNA yielded two bands, one
with the expected size and a smaller band, whereas in
platelets only the expected PCR product was observed
(Online Supplementary Figure S4). Sanger analysis of leuko-
cytes showed that c.3379+1G>A caused exon 25 skipping,
leading to a frameshift at position 1075 and adding 88
aberrant amino acids before a PTC was encountered
(p.Pro1075ValfsTer88). On NGS, however, two aberrant
transcripts were detected: the major one, which lacked
exon 25, was detected in 43% of all reads, and the minor
one, which resulted from activation of a cryptic donor
splice site (DSS) 31 nucleotides upstream from the WT-
DSS, was found in 1.4% of reads (p.Pro1117ValfsTer88)
(Table 2 and Online Supplementary Table S4). In platelets,
however, the mutated allele had undergone NMD, which
precluded observation of aberrant transcripts. 
The c.5664+2T>C mutation was identified in a type 1
VWD patient (UMP03), in trans with the p.Leu2407Pro
mutation. To analyze the PSSM in intron 33, the exon 30-
35 region was amplified. The PCR product had the expect-
ed size in platelets, whereas an additional smaller one was
observed in leukocytes (Figure 1). Sanger sequencing of
the leukocyte PCR product confirmed exon 33 skipping
(p.Gly1874AlafsTer32) (Table 2). NGS detected 2 aberrant
N. Borràs et al.
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Figure 1. Analysis of the c.5664+2T>C mutation in patient UMP03. A) RT-PCR products amplified with primers located in exons 30 and 35 in leukocyte (L) and
platelet (P) RNA, separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR products from patient leukocytes (L2) and platelets (P), and control leuko-
cytes (L). Analysis of the band 2 from patient leukocyte on agarose gel demonstrates exon 33 skipping. In platelets, only the allele without c.5664+2T>C mutation
could be amplified. C) NGS of PCR products from leukocytes showed exon 33 skipping, indicated by arrows depict aberrant transcripts. However, exon 33-34 skipping
was also detected, but in a really low of transcripts. D) Schematic representation of the mutation in genomic DNA and its effect on the VWF mRNA sequence. M indi-
cates a 100-bp DNA ladder.
A B
C
D
transcripts: the major one (37% of reads) showed exon 33
skipping, and the minor (2% of reads) showed exons 33
and 34 skipping. Moreover, analysis of the p.Leu2407Pro
mutation confirmed that NMD of the allele carrying the
c.5664+2T>C mutation had occurred in platelets. 
Candidate intronic mutations
The c.7081+6G>T mutation, identified in a type 1 VWD
patient (UMP04), generated a new GT dinucleotide in
intron 41 (Online Supplementary Table S3). The exon 38-43
region showed the expected PCR product in both cell types
(772 bp). To confirm these results, two informative SNPs
(rs216321 in exon 20 and rs216902 in exon 35) were geno-
typed. Both were in heterozygous state, indicating that the
allele carrying the mutation was unaffected by NMD. 
The c.7730-56C>T mutation (intron 45) was identified
in a type 1 VWD patient (UMP05). The exon 43-49 region,
examined by Sanger and NGS, showed no visible effect on
mRNA splicing. To confirm the presence of the allele car-
rying the intronic mutation, two informative SNPs were
analyzed: rs216321 and rs1800380. Surprisingly, the
sequence obtained in both cell types indicated that only
one allele was expressed. To further explore these results,
we tested whether intron 45 was retained within the
mature mRNA (Online Supplementary Methods) and per-
formed complete sequencing of VWF cDNA from leuko-
cytes. Nonetheless, no changes were observed (data not
shown). 
The c.7730-4C>G mutation (intron 45) was identified in
a type 2A/2M patient (UMP06), combined with the
p.Arg1374Cys mutation. The HSF predicted activation of
a cryptic intronic acceptor splice site (ASS), but in the exon
43-49 region, splicing was not affected by the mutation.
To confirm the presence of the allele carrying c.7730-
4C>G, the p.Arg1374Cys mutation was analyzed, and
both nucleotides were seen in platelets and leukocytes,
suggesting expression of both alleles. We then performed
the same experiment as was done in patient UMP05 to
test intron 45 retention, but no changes in VWF cDNA
were observed (data not shown). 
Effect of VWF mutations on mRNA splicing
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Figure 2. Analysis of the c.546G>A mutation, located at nucleotide 14 from the beginning of exon 6, in patient UMP08. A) RT-PCR products amplified with primers
located in exons 4 and 7 in leukocyte RNA (L), separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR product from patient L (1) showed the single
nucleotide change. C) NGS of PCR products from leukocytes identified the single nucleotide variant, as well as exon 6 skipping. Arrows show aberrant transcripts.
D) Schematic representation of the mutation in genomic DNA and its effect on the VWF mRNA sequence. M indicates a 100-bp DNA ladder.
A B
C
D
The c.8254-5T>G mutation (intron 51) was found in a
type 1 VWD patient (UMP07). The exon 49-52 region was
amplified, and the expected 546-bp size was observed in
both cell types. Sequence analysis by the two techniques
revealed no changes in VWF cDNA. Interestingly, this
patient’s two children, heterozygous for the c.8254-5T>G
mutation, had bleeding symptoms. Hence, we performed
complete sequencing of VWF cDNA from leukocytes.
However, no changes were identified.
Synonymous mutations 
The mutations c.546G>A (exon 6) and c.4866C>T (exon
28) were identified in trans in a type 1 VWD patient
(UMP08). These mutations were studied only in leukocyte
RNA. To investigate c.546G>A, the exon 4-7 region was
amplified, which resulted in the expected band and a
slightly diffuse, smaller band. Sanger sequencing detected
the c.546G>A change (Figure 2). However, NGS not only
detected the nucleotide change, but also recognized a loss
of 125 nucleotides corresponding to exon 6
(p.Thr179ProfsTer31) in small 2.3% of reads (Online
Supplementary Table S4). The predicted impact of the
c.546G>A mutation was discrepant and only two in silico
algorithms predicted an effect on mRNA splicing (Online
Supplementary Table S3) that was confirmed in vivo even
though with a slight effect. To study c.4866C>T, the exon
25-31 region was amplified and sequenced, but no effect
on mRNA processing was seen, as was predicted by in sil-
ico tools. Both nucleotides were identified in heterozygous
state, indicating the presence of both alleles. Only off-
spring carrying the c.546G>A mutation (1 of 3 children)
had lower levels of VWF:Ag and VWF:RCo compared to
N. Borràs et al.
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Figure 3. Analysis of the c.1109G>A (p.Cys370Tyr) mutation in patient UMP10, located in the last nucleotide of exon 9. A) RT-PCR products amplified with primers
located in exons 6 and 12 in leukocyte (L) and platelet (P) RNA, separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR product from patient L (2)
showed exon 9 skipping. The L (3) band could not be purified in the agarose gel due to low concentration, thus it was not analyzed by Sanger. In platelets, only the
non-mutated allele could be amplified.  C) NGS of PCR products from leukocytes identified transcripts lacking exon 9, as well as transcripts lacking exons 8 and 9.
D) Schematic representation of the mutation in genomic DNA and its effect on the VWF mRNA sequence. M indicates a 100-bp DNA ladder.
A B
C
D
the others. This may be explained by the mutation and/or
other factors not explored in the current study.
The c.3291C>T mutation (exon 25), was identified in
patient UMP09 (female), as well as a novel mutation in F8
(c.1346C>G, p.Ala430Gly). Of note, her brother, who was
not included in this study, also had these mutations. As
both siblings experienced bleeding, and the HSF predic-
tion regarding c.3291C>T interpreted creation of an exon-
ic splicing silencer site that could potentially alter splicing,
we hypothesized that this synonymous mutation could
have an effect on VWF mRNA processing. Hence, the
exon 22-26 region was amplified, but no change in the
VWF cDNA sequence was observed. In addition, we test-
ed whether intron 25 was retained within mature VWF
mRNA (Online Supplementary Methods), but no differences
compared to control leukocyte cDNA were found (data not
shown). Finally, as both siblings presented similar FVIII:C
levels, we investigated X chromosome inactivation in
patient UMP09. The results demonstrated skewed inacti-
vation of the WT X chromosome in this patient (Online
Supplementary Figure S5).
Missense mutations
The mutation c.1109G>A (p.Cys370Tyr, exon 9) was
identified in a type 3 VWD carrier (UMP10). The exon 6-
12 region was investigated. Whereas the expected size
was observed in platelets, amplification from leukocytes
resulted in 2 additional bands of   ̴650 and   5̴00 bp (Figure
3). Sanger sequencing of leukocyte mRNA confirmed that
the 650-bp band corresponded to a transcript lacking exon
9. NGS of leukocyte mRNA revealed 3 different tran-
scripts: the WT, a transcript skipping exon 9
(p.Glu333AlafsTer87) (13% of reads), and a transcript
skipping exons 8 and 9 (p.Ser292ThrfsTer87) (7% of
reads)(Table 2). Sequencing of PCR products from
platelets showed no changes, suggesting that the mutated
allele had experienced NMD. 
Duplication mutation
The c.3223-7_3236dup mutation, which generated an
in-frame tandem duplication of 21 nucleotides, including
7 nucleotides from intron 24 and the first 14 from exon
25, was detected in a type 1 VWD patient (UMP11).
Study of this mutation by the two techniques demon-
strated a change in the native ASS of intron 24 in both cell
types, which resulted in maintaining the 21-bp insert cor-
responding to 7 aberrant amino acids in mature VWF
mRNA (p.Pro1079_Tyr1080insLeuGlnValAspProGluPro)
(Table 2 and Online Supplementary Figure S6). Furthermore,
NGS showed that the aberrant mRNA transcript was
Table 2. Effect of VWF mutations on mRNA from leukocytes and platelets.
Mutation type NT change AA change Exon Intron Leukocyte effect Platelet effect Protein prediction
Intronic c.1533+1G>A - - 13 Exon 13 skipping (r.1433_1533del) NMD p.Gly478AlafsTer138
c.3379+1G>A* - - 25 Exon 25 skipping (r.3223_3379del) NMD p.Pro1075ValfsTer88
Activation of a cryptic site at +126 nt NMD p.Pro1117ValfsTer88
in exon 25 (r.3349_3379del) ‡
c.5664+2T>C - - 33 Exon 33 skipping (r.5621_5664del) NMD p.Gly1874AlafsTer32
Exon 33+34 skipping (r.5621_5842del) ‡ NMD p.Phe1875_Cys1948del
c.7081+6G>T - - 41 No visible effect No visible effect -
c.7082-2A>G † - - 41 Activation of a cryptic site +7 nt NMD p.Ala2361GlyfsTer40
in exon 42 (r.7082_7088del)
c.7730-4C>G - - 45 No visible effect No visible effect -
c.7730-56C>T - - 45 No visible effect No visible effect -
c.8254-5T>G - - 51 No visible effect No visible effect -
Synonymous c.546G>A † p.Ser182 6 - Exon 6 skipping (r.533_657del) ‡ NA p.Thr179ProfsTer31
c.3291C>T p.Cys1097 25 - No visible effect No visible effect -
c.3426T>C p.Cys1142 26 - No visible effect No visible effect -
c.4866C>T p.Asp1622 28 - No visible effect NA -
c.7437G>A p.Ser2479 43 - Exon 43 skipping (r.7288_7437) NA p.Val2430GlyfsTer335
Activation of a cryptic site at +146 nt NA p.Ser2479AlafsTer23
in exon 43 (r.7434_7437del)
Missense c.449T>C p.Leu150Pro 5 - No visible effect No visible effect -
c.1109G>A p.Cys370Tyr 9 - Exon 9 skipping (r.998_1109del) NMD p.Glu333AlafsTer87
Exon 8+9 skipping (r.875_1109del) NMD p.Ser292ThrfsTer87
DelIns c.3485_3486delinsTG p.Pro1162Leu 26 - No visible effect No visible effect -
c.3223-7_3236dup p.Pro1079_Tyr1080insLeu
GlnValAspProGluPro 25 - (r.3477_3478instttgcaggtggaccccgagcc) (r.3477_3478instttgcaggt p.Pro1079_Tyr1080insLeu
ggaccccgagcc) GlnValAspProGluPro
c.6699_6702dup p.Cys2235ArgfsTer8 38 - No visible effect NMD p.Cys2235ArgfsTer8
AA:amino acid; NA: not available; NMD: nonsense-mediated decay; NT:nucleotide. *Previous functional studies by Nesbitt et al.23 †Previous functional studies by Corrales et al.7 ‡Leukocyte effect
observed in a really low % of reads by NGS. 
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present in   ̴ 14% of reads in both cell types (Online
Supplementary Table S4). 
Combined potential splice site mutations in individual
patients
The c.7082-2A>G mutation (intron 41) was identified in
a type 3 VWD patient (UMP12) combined in transwith the
p.Leu150Pro (c.449C>T, exon 5) mutation. To study
c.7082-2A>G, the exon 38-43 region was amplified in
platelets and leukocytes, which yielded a band of the
expected size. However, Sanger and NGS sequencing of
the PCR products revealed activation of a cryptic ASS
within exon 42. This led to deletion of the 7 initial
nucleotides of exon 42 (r.7082_7088del), as was predicted
by the 4 algorithms, and resulted in a frameshift and a
PTC (p.Ala2361GlyfsTer40) (Figure 4). Additionally, NGS
showed that the aberrant transcript was present in 24% of
reads. On sequencing of platelet amplicons, there were no
changes, a finding highly suggestive of NMD. As type 3
VWD is characterized by absent or non-functional expres-
sion of both VWF alleles, we postulated that the
p.Leu150Pro missense mutation could have an effect on
VWF mRNA. Nonetheless, no sequence change was iden-
tified. These results were confirmed by analysis of 2
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Figure 4. Analysis of the
c.7082-2A>G mutation in
patient UMP12. Agarose gel
electrophoresis results of RT-
PCR amplification of exon 38
to 43 using RNA from leuko-
cytes and platelets were the
same as those of healthy
controls (data not shown). A)
Traditional Sanger sequenc-
ing of PCR product from
patient leukocyte (L) demon-
strate activation of a cryptic
splice site 7 nucleotides
downstream of the native
splice site within exon 42. In
patient platelet (P), only the
allele carrying the
p.Leu150Pro mutation could
be amplified. B) NGS of PCR
products from leukocytes
showed deletion of the 7 ini-
tial nucleotides of exon 42.
Arrows show aberrant tran-
scripts. C) Schematic repre-
sentation of the mutation in
genomic DNA and its effect
on the VWF mRNA sequence.
WO: without.
A
B
C
informative SNPs, rs1800375 and rs1800376, which were
found in heterozygous state in leukocyte transcripts and
homozygous state in platelets. 
The c.[3426T>C; 3485_3486delinsTG] mutations (exon
26) were found in a type 2A VWD patient (UMP13), com-
bined in trans with p.Cys2773Ser. In silico analysis predict-
ed no impact on the splice site for c. 3485_3486delinsTG,
but 2 of the 4 algorithms predicted that c.3426T>C would
have an effect on splicing. The exon 25-28 region was
investigated, but no effect was found on mRNA process-
ing. Study of the p.Cys2773Ser mutation and 2 informa-
tive SNPs (rs2228317 and rs4021576) confirmed that the 2
alleles were present, suggesting that exon 26 mutations do
not have an effect on VWF splicing.
The mutations (c.7437G>A exon 43), and
c.6699_6702dup (p.Cys2235ArgfsTer8, exon 38) were
identified in trans in a severe type 1 VWD patient
(UMP14) and studied only in leukocyte RNA. For
c.7437G>A, we amplified exons 41-45, and 2 bands
emerged: one with the expected size, and a smaller band
of   ̴̴350 bp (Figure 5). Sequencing analysis by both tech-
niques revealed 2 aberrant transcripts: one lacked exon
43 (p.Val2430GlyfsTer335) and the other showed activa-
tion of a cryptic DSS within exon 43, leading to deletion
of its 4 final nucleotides (p.Ser2479AlafsTer23) (Table 2).
Study of c.6699_6702dup in leukocyte mRNA showed
no splicing changes, but the duplication introduced 4
nucleotides that changed the reading frame and generat-
ed a PTC (p.Cys2235ArgfsTer8).
The c.546G>A (p.=, exon 6) and c.7082-2A>G (intron
41) mutations in transwith c.8155+3G>C (intron 50) were
detected in a type 3 VWD patient (UMP15). This patient
had been described in our previous article, but at that time
we were only able to identify the effect of c.8155+3G>C
(p.Gly2706ValfsTer24) on splicing. On reanalysis of this
case with NGS, we were able to characterize the effect of
c.546G>A (p.Thr179ProfsTer31) and c.7082-2A>G
(p.Ala2361GlyfsTer40) in cis in leukocyte mRNA. The
results are consistent with those observed in patients
UMP08 and UMP12, who harbored each mutation indi-
vidually. In addition, in leukocytes, transcripts resulting
from c.546G>A were detected in 2% of reads, transcripts
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Figure 5. Analysis of the c.7437G>A (p.=) mutation in patient UMP14, located in the last nucleotide of exon 43. A) RT-PCR products amplified with primers located
in exons 41 and 45 in leukocyte RNA (L), separated on 1% agarose gel. B) Traditional Sanger sequencing of PCR product from patient leukocyte (L) shows two aber-
rant transcripts: activation of a cryptic splice site - 4 nucleotides upstream to WT-DSS - in exon 43 (1), and exon 43 skipping (2). C) NGS of PCR products gave the
same results than Sanger sequencing. D) Schematic representation of the mutation in genomic DNA and its effect on the VWF mRNA sequence. M indicates a 100-
bp DNA ladder. WO: without.
A B
C
D
from c.7082-2A>G in 6% and transcripts from
c.8155+3G>C in 95% of reads.  In platelet analyses, NGS
detected transcripts without exon 6 resulting from the
c.546G>A mutation in 11% of the total reads but no aber-
rant transcript derived from the mutation c.7082-2A>G
indicating that NMD rate could differ between 5' and 3'
regions of mRNA. These results indicate the c.[546G>A;
7082-2A>G] allele is under-represented compared to the
allele carrying the c.8155+3G>C mutation, showing that
this allele underwent NMD in both cell types, as was pre-
viously hypothesized.7
Discussion
This study reports the results of in-depth analysis of 18
PSSM in samples from VWD patients. The novel and
robust procedure used, combining two-step RT-PCR and
NGS sequencing, was faster and more sensitive than the
method used in our previous article.7 This new approach
provides several advantages, such as allele-specific indi-
vidual sequences, higher sensitivity to detect transcript
variants present at low copy numbers, and simplified sam-
ple preparation. Moreover, the NGS data on total reads
obtained for each transcript is additional information that
can provide an approximation of the expression levels of
each VWF mRNA. Studies are currently ongoing to con-
firm that the relative expression of each transcript
obtained by NGS is comparable to that provided by real-
time RT-PCR. 
The proven usefulness of leukocyte analysis to interpret
mutations masked by NMD in platelets was seen in rela-
tion to the c.3379+1G>A mutation, which had been pre-
viously investigated by RT-PCR in platelets.23 In that study,
the true pathogenic effect of this mutation could not be
determined due to NMD. In the present study, using
leukocyte mRNA and NGS technology, we found that the
mutation induces two aberrant transcripts. 
Similarly, the pathogenic mechanism of 7 PSSM
(c.1533+1G>A, c.5664+2T>C, c.7082-2A>G, c.546G>A,
c.7437G>A, and p.Cys370Tyr) was determined in leuko-
cytes, and only the c.3223-7_3236dup mutation effect was
observed in both cell types. Because this mutation is locat-
ed in the D3 domain implicated in multimerization, it is
possible that the pathogenic mechanism leading to type 1
VWD may be related to impaired VWF secretion due to
intracellular retention, as has been described for other D3
mutations such as p.Cys1130Phe.24 To confirm this
hypothesis, expression studies by means of heterologous
cell lines or blood outgrowth endothelial cells (BOECs)
will remain the gold standard. 
As would be expected, mutations located in the consen-
sus splicing sequence affected mRNA processing. These
included c.1533+1G>A, c.5664+2T>C, leading to exon
skipping, and c.7082-2A>G, activating a cryptic splice site.
Both these molecular effects have been reported previous-
ly in splicing mutations causing VWD.7,25,26 The c.7082-
2A>G in trans with p.Leu150Pro leads to the development
of type 3 VWD. The p.Leu150Pro mutation does not affect
splicing. However, other mutations located in the propep-
tide, such as p.Asp141Tyr, have been identified in type 3
patients,27 and, as has been described in these cases, we
suspect that p.Leu150Pro may compromise propeptide
folding and affect intracellular survival and the capacity to
mediate multimerization. The c.1533+1G>A mutation in
leukocytes generated three aberrant transcripts. One of
them, which leads to the inframe deletion of exons 13-14,
should have been detected in platelets since it would not
generate a PTC and would not be degraded. However,
because the mutation is located in a region with weak
splicing signal sequences, as previously demonstrated,7,25,26
we suggest that the results obtained in leukocytes could
be an artifact that would not occur in the natural cellular
type of VWF expression. Based on these observations, we
propose that the real effect of c.1533+1G>A is the skip-
ping of exon 13, which predicts a frameshift at position
478 and addition of 138 aberrant amino acids before a
PTC is encountered (p.Gly478AlafsTer138).
Two synonymous mutations included in our study,
c.546G>A and c.7437G>A, affect splicing of VWFmRNA.
To our knowledge, only three synonymous mutations
affecting VWF mRNA processing have been reported:
c.7056C>T,28 c.7464C>T,29 and c.3390C>T.26 Of note, the
results of the present study have almost doubled the num-
ber of reported mutations of this type causing VWD. The
pathogenic effect of c.546G>A could only be documented
by NGS; it eluded Sanger detection because of the low
expression in leukocytes and platelets. The c.7437G>A
mutation located at the last nucleotide of exon 43 was
found in a patient with severe type 1 VWD (UMP14)
in trans with c.6699_6702dup (p.Cys2235ArgfsTer8). This
synonymous mutation produced 2 splicing variants. First,
creation of a new DSS 4 nucleotides upstream of the WT-
DSS in exon 43 that generated a PTC in exon 44 and
would lead to NMD in platelets; and second, exon 43 skip-
ping and generation of a PTC in exon 52. In this latter case,
we would expect that NMD had been abolished in
platelets, since this cellular mechanism is not effective
when a PTC is encountered within 50 bp of the last exon-
exon junction.30 
Study of the p.Cys370Tyr (c.1109G>A in exon 9) muta-
tion, resulted in generation of 2 VWF transcripts, one of
them identified only by NGS because of their low expres-
sion. Of note, only one other missense mutation,
p.Gly1108Arg, has been reported to affect VWF splicing.
Thus, these two mutations support the concept that mis-
sense mutations on the last exonic nucleotides can also
have repercussions on the splicing process.31 Interestingly,
the pathogenic effect of this mutation is the same as that
described for c.1109+2T>C (intron 9).32 In addition to the
patient reported here, the p.Cys370Tyr mutation was
identified in 6 additional related patients included in the
PCM-EVW-ES: in homozygous state in a type 3 VWD
patient and in heterozygosis in 4 type 3 carriers and 1
patient with type 1 VWD, based on their phenotype lev-
els. Certain genetic modifiers of VWF levels33 and inter-
individual variability in NMD efficiency between patients
carrying identical mutations may lead to differences in the
disease severity and clinical phenotype.34 
Lastly, study of c.7081+6G>T, c.7730-4C>G, c.7730-
56C>T, c.8254-5T>G, c.3291C>T, c.4866C>T and
c.[3426T>C; 3485_3486delinsTG] showed no visible
effect on mRNA processing, although this does not neces-
sarily mean that they have no effect on splicing. For
instance, mRNA SNP analysis in patient UMP05 with
c.7730-56C>T showed an absence of 1 allele in leukocytes
and platelets, suggesting that the allele may have experi-
enced NMD in both cell types or lack expression due to a
mutation that was not detected by our sequencing proto-
col. Of particular note, deep intronic mutations such as
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c.6599-20A>T have been found to cause VWD.35 In patient
UMP07 carrying the c.8254-5T>G mutation, no informa-
tive SNP was identified and we were unable to determine
whether there was a lack of expression of 1 allele, which
could explain cosegregation of the mutation in the family
with bleeding symptoms.  
Study of c.[3426T>C; 3485_3486delinsTG] and c.7730-
4C>G showed no visible effect on splicing. However,
these mutations have been identified in homozygous state
in a type 3 patient (c.[3426T>C; 3485_3486delinsTG])3
and in a severe type 1 VWD patient (c.7730-4C>G)4 with
VWF:Ag at 7% and VWF:RCo at 5%, combined with the
heterozygous p.Ala631Val (previously reported in a
healthy control).36 Based on these findings, there is sub-
stantial evidence that these mutations would have an
effect on VWF levels. Therefore, to unequivocally deter-
mine the potential deleterious effect of these variants,
functional studies remain essential. These studies are tra-
ditionally carried out by in vitro analyses performed using
heterologous cell lines (COS7, AtT-20 and HEK293).
However, the advent of the possibility of obtaining
BOECs from patients represents a valuable alternative,
since this is the functional expression site of VWF.37
Moreover, BOECs allows protein expression and mRNA
studies simultaneously.
In silico algorithms used to assess the impact of mutations
on splicing are more sensitive and accurate in determining
the putative effect of intronic mutations than that of syn-
onymous or missense mutations, such as c.546G>A and
p.Cys370Tyr. Therefore, the results here should not be con-
sidered definitive, and as with all analytical approaches,
should form one aspect of a wider investigation.5
In conclusion, we present an extensive study reporting
the effect of 18 candidate mutations on VWF mRNA pro-
cessing. In vivomRNA studies incorporating NGS technol-
ogy together with traditional sequencing enabled us to
determine the pathogenic effect of 8 PSSM (44%). Our
study emphasizes the importance of examining selected
mutations, including synonymous and missense muta-
tions, to determine their pathogenic role in splicing. Taken
together, our results add to the current knowledge about
the molecular events leading to VWD.  
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